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A b s t r A c t
No clear evidence exists regarding the effect of atrial fibrillation (AF) duration and 
frequency on the occurrence of stroke. Some studies have suggested a lower stroke 
risk in paroxysmal than in persistent AF. In contrast, other studies have reported a 
comparable stroke risk of paroxysmal to permanent AF. Upcoming trials such as the 
TRENDS and the ASSERT studies will provide further insight into the direct relation 
of AF duration and systemic embolism in a large group of patients with an implantable 
device. Recently, an ACC/AHA physician consortium provided clinical performance 
measures for adults with nonvalvular atrial fibrillation or atrial flutter. 
I N D r O D U c t I O N
Atrial fibrillation (AF) remains a challenge to manage. Although there are issues 
concerning rate and rhythm control, prevention of thromboembolism remains the 
most important aspect of management. Untreated, strokes will occur in about 2% 
to 5% of patients per year, and the strokes caused by AF can be quite devastating 
[1-3]. Anticoagulant therapy with vitamin K antagonists such as warfarin sodium 
can substantially reduce the risk of AF–related thromboembolism, but at the risk of 
incurring more hemorrhagic complications [1].
Accurate stratification of patients with AF by thromboembolism risk should ideally 
target the use of warfarin for patients at highest risk of thromboembolism and reduce 
the exposure of low-risk patients to the complications of warfarin [4-6].
P A r O x Y s m A L  v s  P E r m A N E N t  A t r I A L  f I b r I L L A t I O N
Several risk stratification models of different complexity have been introduced 
to identify AF patients who benefit from oral anticoagulation [7]. In none of these 
models, the type of AF—paroxysmal versus persistent or permanent—has emerged as 
an independent predictor of thromboembolic events. Thus, the most recent guidelines 
on AF therapy recommend the use of oral anticoagulation for patients with stroke 
risk factors irrespective of the type of AF [2]. Paroxysmal AF is a self-terminating 
arrhythmia, within a short period of time, often less than 24 hours [2].
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A subanalysis of the SPAF (Stroke Prophylaxis in Atrial 
Fibrillation) trials looked at the risk of stroke in patients 
having “intermittent” AF in comparison with those having 
continuous AF [8]. This study in 460 patients with paroxysmal 
AF found similar incidence of thromboembolic events for both 
types of AF. However, the definition of intermittent AF was 
completely different from what we now agree is paroxysmal 
AF [2]. Furthermore, this analysis was based on the SPAF 
trials conducted more than 15 years ago and was limited to 
patients treated with aspirin. Treatment for AF and for the 
underlying cardiovascular disease has markedly changed, for 
instance regarding therapy for arterial hypertension or current 
international normalized ratio (INR) management. Finally, 
Hart et al. used only data from patients treated with aspirin 
and not with oral anticoagulation.
The observational Euro Heart Survey on AF (2003–04) 
enrolled 150 paroxysmal, 110 persistent, and 1515 
permanent AF patients, according to the 2001 American 
College of Cardiology, American Heart Association, and 
the European Society of Cardiology guidelines definitions 
[]. A 1-year follow-up was completed. Permanent AF 
patients had at baseline a worse stroke risk profile than 
paroxysmal and persistent AF patients. In paroxysmal AF, 
the risk for stroke, any thromboembolism, major bleeding 
and the combined endpoint of cardiovascular mortality, 
any thromboembolism, and major bleeding was comparable 
in persistent and permanent AF, in both univariable and 
multivariable analyses.
This observation is consistent with the results reported 
by Hohnloser et al [10]. The data provided by Honhloser et 
al. were derived from the patients enrolled in the ACTIVE 
W trial (Atrial Fibrillation Clopidogrel Trial With Irbesartan 
for Prevention of Vascular Events). The ACTIVE W was a 
trial comparing oral anticoagulation to combined antiplatelet 
therapy with aspirin and clopidogrel for prevention of vascular 
events in 6,706 AF patients. The incidence of thromboembolic 
events and major bleeds were compared in patients with 
paroxysmal and persistent or permanent AF. The above 
mentioned data may explain observations made in other 
contemporary trials such as the AFFIRM (Atrial Fibrillation 
Follow-up Investigation of Rhythm Management) trial [11]. In 
the AFFIRM trial, the prevalence of ischemic stroke was 7.1% 
in patients in whom rhythm control was attempted, compared 
with 5.5% in those who were randomized to rate control. It 
is possible that episodes of (asymptomatic) paroxysmal AF 
in the rhythm control arm for which patients did not receive 
anticoagulation therapy may account for this finding.
On the other hand, emerging evidence suggests that brief 
episodes of self-terminating AF do not constitute the same 
risk as long-lasting AF [12]. Comparison of stroke rates in 
the anticoagulation-treated arms of several trials in relation 
to proportion with paroxysmal AF showed that trials with a 
higher proportion of patients with paroxysmal AF usually 
have a lower risk of stroke [13]. Two large studies examining 
the relevance of duration of AF (“burden”) to the risk of 
thromboembolism using device telemetry are currently in 
progress [14,15].
P E r f O r m A N c E  m E A s U r E s  f O r  A t r I A L 
f I b r I L L A t I O N
The American Heart Association and the American 
College of Cardiology have jointly issued clinical performance 
measures for adults with nonvalvular atrial fibrillation (AF) or 
atrial flutter, which were published concurrently in the Journal 
of the American College of Cardiology and Circulation [16]. 
Three performance risk measures were identified: assessment 
of thromboembolic risk factors, long-term anticoagulation 
therapy, and monthly INR measurement.
The following are 10 points to remember from this 
scientific statement.
 1. Antithrombotic therapy is indicated for all patients with 
AF except those with lone AF or contraindications.
 2. Assessment of thromboembolic risk factors should include 
prior stroke/transient ischemic attack (TIA), age ≥75 years, 
hypertension, diabetes, and heart failure or left ventricular 
(LV) systolic dysfunction.
 3. Prior stroke/TIA is the strongest risk factor and is an 
indication for anticoagulation with warfarin.
 4. Rheumatic mitral stenosis also is a strong risk factor for 
stroke and is an indication for warfarin even if no other 
risk factors are present.
 5. Warfarin also is indicated for patients with >1 moderate 
risk factor (age ≥75 years, hypertension, diabetes, and 
heart failure/LV systolic dysfunction)
 6. Aspirin may be used for stroke prevention in patients 
without any risk factors.
 7. Antithrombotic therapy (warfarin or aspirin) should 
be used on an individualized basis in patients with one 
moderate risk factor. 
 8. The international normalized ratio (INR) initially should 
be measured at least once per week and then once per 
month after a stable degree of anticoagulation when an 
INR of 2-3 is achieved.
 . When aspirin is used for stroke prevention, the daily dose 
should be 81-325 mg/day.
 10. Patients with AFl should receive antithrombotic therapy 
in the same fashion as patients with AF.
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